# Bioequivalence Study to Compare Two Formulations of Deanxit®

> **NCT03472651** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** test treatment: flupentixol/melitracen
- **DRUG:** reference treatment: flupentixol/melitracen

## Key facts

- **NCT ID:** NCT03472651
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-07
- **Primary completion:** 2018-06-28
- **Final completion:** 2018-06-28
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472651, "Bioequivalence Study to Compare Two Formulations of Deanxit®". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03472651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*